Evaluating the Effectiveness of the Computer-Based Education Platform, Pharmacy5in5, on Pharmacists’ Knowledge of Anticholinergic Toxicity Using a Randomized Controlled Trial
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Recruitment
2.3. Study Procedure
2.4. Interventions
2.4.1. Computer-Based Educational Platform
- Quizzes: each module consists of one “Fast Fact quiz” and six “Case-based quizzes” that are based on the module learning objectives. The “Fast Fact quiz” tests users’ basic knowledge about the clinical topic, while “Case-based quizzes” test users’ knowledge and behaviour through helping a fictional pharmacist make the optimal decision in cases based on real-life scenarios. Questions used are multiple choice or true/false.
- Feedback: in each module, online quizzes are followed with feedback on users’ performance. Each “Fast Fact quiz” provides users with immediate feedback after each question to let them know if they got the right answer. “Case-based quizzes” provide delayed feedback after the user finishes the whole quiz series, along with the correct answer, rationale, and links to useful resources underneath each question.
- Peer comparison: this feature aims to compare a user’s performance to an average user and provides feedback on user progress. Peer comparison also rewards users who outperform an average user, and motivates users who perform below average.
- Self-reflection: after each case-based quiz, users are asked to answer a question about their past behaviour. Self-reflection questions are structured as follows: “in the past 3 months have you/did you…”. This feature allows users to self-report their behaviours, which can help detect any changes in users’ behaviour before and after taking the module.
- Multimedia resources: there is a set of specific resources created for each module, including: flashcards, infographics, and short videos. These multimedia resources highlight the key take home message for each clinical topic and can be shared on social media.
2.4.2. Printed Materials
2.5. Anticholinergic Toxicity Module Development and Validation
- Recognize anticholinergic side effects when assessing patients, including anticholinergic toxicity.
- Identify higher risk anticholinergic drugs, including additive effects.
- Classify patients according to their risk for serious anticholinergic side effects.
- Identify safer alternatives for indications where anticholinergic drugs are commonly used.
- Implement a plan to switch an anticholinergic drug to a safer alternative, deprescribing, tapering, switching, and incorporating washout periods.
2.6. Outcome Measure
2.7. Sample Size Calculation
2.8. Randomization and Blinding
2.9. Data Analysis
2.10. Knowledge Test Development and Validation
2.10.1. Knowledge Test Development
2.10.2. Knowledge Test Validation
3. Results
3.1. Demographics of Participants
3.2. Loss to Follow Up
3.3. Assessment of Access to the Anticholinergic Toxicity Module
3.4. Knowledge Test
4. Discussion
4.1. Strengths and Limitations
4.2. Practical Implications and Future Research
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
Appendix A. Content Validity Index of the Knowledge Test Items (33 Items)
Evaluator | |||||||||
---|---|---|---|---|---|---|---|---|---|
Question | Exp1 | Exp2 | Exp3 | Exp4 | Exp5 | Exp6 | Exp7 | Total # of Experts Voting 3 or 4 | I-CVI Score |
1 | 4 | 2 | 4 | 4 | 1 | 4 | 3 | 5 | 71.42857143 |
2 | 3 | 4 | 4 | 4 | 2 | 4 | 4 | 6 | 85.71428571 |
3 | 3 | 4 | 3 | 3 | 1 | 4 | 3 | 6 | 85.71428571 |
4 | 4 | 4 | 3 | 1 | 4 | 3 | 4 | 6 | 85.71428571 |
5 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 7 | 100 |
6 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 6 | 85.71428571 |
7 | 4 | 4 | 3 | 3 | 4 | 3 | 4 | 7 | 100 |
8 | 3 | 2 | 2 | 3 | 3 | 3 | 4 | 5 | 71.42857143 |
9 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 7 | 100 |
10 | 4 | 3 | 4 | 4 | 1 | 4 | 4 | 6 | 85.71428571 |
11 | 2 | 3 | 2 | 3 | 4 | 3 | 4 | 5 | 71.42857143 |
12a | 3 | 2 | 3 | 4 | 4 | 3 | 4 | 6 | 85.71428571 |
12b | 3 | 2 | 3 | 4 | 4 | 3 | 4 | 6 | 85.71428571 |
12c | 3 | 3 | 3 | 4 | 2 | 2 | 4 | 5 | 71.42857143 |
12d | 4 | 3 | 4 | 4 | 2 | 4 | 4 | 6 | 85.71428571 |
13a | 3 | 4 | 4 | 4 | 2 | 3 | 4 | 6 | 85.71428571 |
13b | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 7 | 100 |
13c | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 7 | 100 |
14a | 4 | 4 | 3 | 4 | 2 | 3 | 4 | 6 | 85.71428571 |
14b | 3 | 4 | 4 | 3 | 4 | 3 | 4 | 7 | 100 |
14c | 3 | 4 | 4 | 3 | 2 | 3 | 4 | 6 | 85.71428571 |
14d | 4 | 4 | 4 | 4 | 1 | 2 | 4 | 5 | 71.42857143 |
14e | 4 | 4 | 4 | 4 | 1 | 4 | 4 | 6 | 85.71428571 |
14f | 3 | 4 | 4 | 3 | 1 | 3 | 3 | 6 | 85.71428571 |
15a | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 7 | 100 |
15b | 3 | 4 | 4 | 4 | 2 | 3 | 4 | 6 | 85.71428571 |
15c | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 7 | 100 |
16a | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 7 | 100 |
16b | 4 | 4 | 4 | 4 | 1 | 3 | 4 | 6 | 85.71428571 |
16c | 3 | 4 | 3 | 4 | 1 | 3 | 4 | 6 | 85.71428571 |
16d | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 7 | 100 |
17 Rx1 | 4 | 4 | 4 | 2 | 3 | 3 | 4 | 6 | 85.71428571 |
17 Rx2 | 4 | 4 | 4 | 2 | 3 | 2 | 4 | 5 | 71.42857143 |
Appendix B. The Final Version of the Knowledge Test (22 Items)
(Q1) Which of the following factors/situations can worsen or intensify anticholinergic side effects?
|
(Q2) Which of the following antidepressant drugs has less anticholinergic activity than paroxetine, which is highly anticholinergic?
|
(Q3) A patient has been taking baclofen for many years, and is complaining of dry mouth, dry skin and difficulty urinating. Recently tramadol was added to their therapy. Which of the following would you expect to happen?
|
(Q4) Symptoms of mild anticholinergic toxicity include:
|
(Q5) A patient has taken paroxetine for many years with no reported anticholinergic effects. After 10 years, at the age of 72, the patient starts to notice some dry mouth. Could paroxetine be causing these symptoms now, even though it was not in the past?
|
(Q6) Symptoms of anticholinergic effects can occur within:
|
(Q7) A patient taking oxcarbazepine who complains of urinary retention and dry skin is switched to lamotrigine. How would you expect their complaints to be affected by the drug change?
|
(Q8) P.J. is a frail 81-year-old male patient with hypertension and insomnia. His current medication list includes: doxepin 3 mg once daily at bedtime and lisinopril 10 mg once daily. (Q8.a) Which of the following factors put P.J. at higher risk for serious anticholinergic side effects?
|
Today P.J. comes to your pharmacy complaining of dry mouth and urinary retention for the past 3 days. Last week, P.J.’s doctor increased the doxepin dose to 6 mg once daily at bedtime to help address his symptoms of insomnia. P.J. tells you that he has been taking 2 tablets of doxepin 6 mg at bedtime since he could not sleep. (Q8. b) What could you do to help P.J.?
|
(Q9) M.K., a 52-year-old female patient, comes to the pharmacy to ask for your recommendation for the appropriate dose for loperamide. She has been experiencing mild diarrhea for the past two days. She is not taking any chronic medications or OTC drugs other than acetaminophen for an occasional headache. (Q9.a) Loperamide is classified as a drug with what level of anticholinergic activity?
|
(Q9.b) M.K. has one or more attributes that put her at risk for serious anticholinergic side effects.
|
(Q9.c) Which measure(s) should you take/recommend to help prevent anticholinergic toxicity with her use of loperamide?
|
(Q10) H.A. a 71-year-old man, comes to your pharmacy complaining of back pain for the past 2 days after lifting a heavy bag. He asks for your advice on taking an OTC muscle relaxant with methocarbamol. After a thorough assessment, you determine that H.A. is not taking any prescribed medications. He only takes diphenhydramine every other night to help him sleep. (Q10.a) Methocarbamol is classified as a drug with what level of anticholinergic activity?
|
(Q10.b) What would you recommend to help H.A. manage his back pain and minimize the chance of any adverse effects from the medication?
|
(Q11) S.S. a 67-year-old female patient with type 2 diabetes, hypertension and dyslipidemia, comes to the pharmacy for a medication review. Her current medication list includes metformin, lisinopril, atorvastatin, ranitidine, ipratropium and oxybutynin. Current blood pressure 126/73, heart rate 90, HbA1C% 6.7, lipid profile within normal range |
(Q11.a) Which of the following drugs is classified as having moderate/high anticholinergic activity?
|
(Q11.b) What other information do you need to collect to better assess for the risk of anticholinergic toxicity?
|
(Q11.c) After completing the medication review and assessment of all S.S’s medications, using the resources provided, please write your recommendation/(s) to S.S.’s family doctor, as you would in your practice site. ……………………………………………………………………………………………………………………………………………………………………………………………………………………… |
(Q12) K.L., a 72-year-old male patient, comes to the pharmacy to pick up his prescription for citalopram. His current medication list includes captopril 12.5 three times daily, risperidone 4 mg daily, ranitidine 150 mg once daily, carbidopa/levodopa 100/25 three times a day, and trazodone 50 mg at bedtime. All his medical conditions are currently stable and he is not complaining of any side effects. He denies taking any over the counter (OTC) medications. (Q12.a) Which of the following factors put K.L. at an increased risk for serious anticholinergic side effects?
|
Three weeks later, K.L. comes back to the pharmacy with a new prescription, increasing the dose for ranitidine 150 mg to twice daily for his ongoing heartburn. (Q12.b) Could this change in K.L.’s drug regimen increase his risk for anticholinergic side effects?
|
(Q12.c) What might you do to help lessen K.L.’s risk for possible anticholinergic side effects?
|
13. Based on your clinical judgement, would you fill the following prescriptions? Please select the best answer from the choices provided, then provide a recommendation according to your choice. |
Rx 1
|
Rx 2
|
Appendix C. Subgroup Analysis of Post-Test Knowledge Multiple Choice Questions
Questions | Study Group | |||
---|---|---|---|---|
Intervention Group n = 50 | Control Group n = 51 | |||
Correct | Incorrect | Correct | Incorrect | |
Q1 | 47 | 3 | 45 | 6 |
Q2 | 36 | 14 | 48 | 3 |
Q3 | 49 | 1 | 40 | 11 |
Q4 | 37 | 13 | 39 | 12 |
Q5 | 43 | 7 | 47 | 4 |
Q6 | 45 | 5 | 44 | 7 |
Q7 | 46 | 4 | 47 | 4 |
Q8.a | 5 | 45 | 12 | 39 |
Q8.b | 44 | 6 | 45 | 6 |
Q9.a | 41 | 9 | 39 | 12 |
Q9.b | 39 | 11 | 41 | 10 |
Q9.c | 48 | 2 | 45 | 6 |
Q10.a | 42 | 8 | 46 | 5 |
Q10.b | 48 | 2 | 48 | 3 |
Q11.a | 48 | 2 | 49 | 2 |
Q11.b | 41 | 9 | 44 | 7 |
Q12.a | 4 | 46 | 13 | 38 |
Q12.b | 44 | 6 | 49 | 2 |
Q12.c | 48 | 2 | 50 | 1 |
Appendix D. Subgroup Analysis of Post-Test Knowledge Open-Ended Questions
Rx | Study Group | |||||
---|---|---|---|---|---|---|
Intervention Group n = 50 | Control Group n = 51 | |||||
Fill as is | fill the prescription with education | Contact prescriber to offer an alternative | Fill as is | fill the prescription with education | Contact prescriber to offer an alternative | |
Rx 1 | 2 | 11 | 37 | 1 | 18 | 32 |
Rx 2 | 2 | 10 | 38 | 1 | 4 | 46 |
References
- Gerretsen, P.; Pollock, B.G. Cognitive risks of anticholinergics in the elderly. Aging Health 2013, 9, 159–166. [Google Scholar] [CrossRef]
- Gerretsen, P.; Pollock, B.G. Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opin. Drug Saf. 2011, 10, 751–765. [Google Scholar] [CrossRef] [PubMed]
- Kachru, N.; Carnahan, R.M.; Johnson, M.L.; Aparasu, R.R. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: A national cross-sectional study. Drugs Aging 2015, 32, 379–389. [Google Scholar] [CrossRef] [PubMed]
- Arseneau, N.; Braden, K. Anticholinergic toxicity, polypharmacy, and inappropriate prescribing. Univ. West. Ont. Med. J. 2016, 84, 31–33. [Google Scholar] [CrossRef]
- Broderick, E.D.; Metheny, H.; Crosby, B. Anticholinergic Toxicity. StatPearls 2020, 38, 31–35. [Google Scholar]
- Green, A.R.; Reifler, L.M.; Bayliss, E.A.; Weffald, L.A.; Boyd, C.M. Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: A retrospective cohort study. Drugs Aging 2019, 36, 289–297. [Google Scholar] [CrossRef] [PubMed]
- Salahudeen, M.S.; Duffull, S.B.; Nishtala, P.S. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr. 2015, 15, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakham, A.; Myint, P.K.; Bond, C.M.; Newlands, R.; Loke, Y.K.; Cruickshank, M. Interventions to reduce anticholinergic burden in adults aged 65 and older: A systematic review. J. Am. Med. Dir. Assoc. 2020, 21, 172–180.e175. [Google Scholar] [CrossRef]
- Moga, D.C.; Abner, E.L.; Rigsby, D.N.; Eckmann, L.; Huffmyer, M.; Murphy, R.R.; Coy, B.B.; Jicha, G.A. Optimizing medication appropriateness in older adults: A randomized clinical interventional trial to decrease anticholinergic burden. Alzheimer’s Res. Ther. 2017, 9, 1–10. [Google Scholar] [CrossRef]
- Pitkälä, K.H.; Juola, A.; Kautiainen, H.; Soini, H.; Finne-Soveri, U.H.; Bell, J.S.; Björkman, M. Education to reduce potentially harmful medication use among residents of assisted living facilities: A randomized controlled trial. J. Am. Med. Dir. Assoc. 2014, 15, 892–898. [Google Scholar] [CrossRef]
- Giguère, A.; Zomahoun, H.T.V.; Carmichael, P.; Uwizeye, C.B.; Légaré, F.; Grimshaw, J.M.; Gagnon, M.; Auguste, D.U.; Massougbodji, J. Printed educational materials: Effects on professional practice and healthcare outcomes. Cochrane Database Syst. Rev. 2020, 8, 398. [Google Scholar] [CrossRef] [PubMed]
- Kouladjian, L.; Chen, T.F.; Gnjidic, D.; Hilmer, S.N. Education and assessment of pharmacists on the use of the drug burden index in older adults using a continuing professional development education method. Am. J. Pharm. Educ. 2016, 80, 463. [Google Scholar] [CrossRef] [PubMed]
- Salter, S.M.; Karia, A.; Sanfilippo, F.M.; Clifford, R.M. Effectiveness of E-learning in pharmacy education. Am. J. Pharm. Educ. 2014, 78, 83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- RPharm, H.M.C.B.; Ram, P.L.; Lakos, A.; GradDipPharm, S.G.; Pharm, L.J.S.B.; Schneider, C.R.; Gregory, L.A.H. Post-Registration Learning Trends of Community Pharmacists. J. Pharm. Pract. Res. 2011, 41, 203–207. [Google Scholar] [CrossRef]
- Trewet, C.B.; Fjortoft, N. Evaluation of the impact of a continuing professional development worksheet on sustained learning and implementing change after a continuing pharmacy education activity. Res. Soc. Adm. Pharm. 2013, 9, 215–221. [Google Scholar] [CrossRef]
- Guze, P.A. Using technology to meet the challenges of medical education. Trans. Am. Clin. Climatol. Assoc. 2015, 126, 260–270. [Google Scholar]
- Reeves, S.; Fletcher, S.; McLoughlin, C.; Yim, A.; Patel, K.D. Interprofessional online learning for primary healthcare: Findings from a scoping review. BMJ Open 2017, 7, e016872. [Google Scholar] [CrossRef] [Green Version]
- Nesterowicz, K.; Fereshtehnejad, S.-M.; Edelbring, S. e-Learning in Continuing Pharmacy Education is effective and just as accepted as on-site learning. Pharm. Educ. 2015, 15, 22–26. [Google Scholar]
- Hussein, R.; Lin, E.C.; Grindrod, K. Effects of computer-based education on health professionals’ knowledge, skills, and behavior: A scoping review. J. Am. Pharm. Assoc. 2021, 61, e44–e68. [Google Scholar] [CrossRef]
- Seybert, A.L.; Smithburger, P.L.; Benedict, N.J.; Kobulinsky, L.R.; Kane-Gill, S.L.; Coons, J.C. Evidence for simulation in pharmacy education. J. Am. Coll. Clin. Pharm. 2019, 2, 686–692. [Google Scholar] [CrossRef]
- Franic, D.M.; Palmer, R.; Fulford, M. Doctor of pharmacy student preferences for computer-based vs. paper-and-pencil testing in a, social and administrative pharmacy course. Curr. Pharm. Teach. Learn. 2021, 13, 819–825. [Google Scholar] [CrossRef] [PubMed]
- Mai, C.-W.; Lee, E.-L.; Wong, P.-S.; Er, H.-M. Evaluation of Computer-based Simulation Learning on Knowledge, Learning Approaches and Motivation among Pharmacy Students. Indian J. Pharm. Educ. Res. 2019, 53, 595–602. [Google Scholar] [CrossRef] [Green Version]
- O’Hare, C.; Girvin, B. A Narrative Overview of the Effectiveness of E-learning in Pharmacy Education. J. Pharm. Pract. Pharm. Sci. 2018, 1, 9–23. [Google Scholar]
- Eysenbach, G.; Group, C.-E. CONSORT-EHEALTH: Improving and standardizing evaluation reports of Web-based and mobile health interventions. J. Med. Internet Res. 2011, 13, e126. [Google Scholar] [CrossRef]
- Edwards, P.J.; Roberts, I.; Clarke, M.J.; DiGuiseppi, C.; Wentz, R.; Kwan, I.; Cooper, R.; Felix, L.M.; Pratap, S. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst. Rev. 2009, 3, 4. [Google Scholar] [CrossRef] [PubMed]
- Thorpe, C.; Ryan, B.; McLean, S.L.; Burt, A.; Stewart, M.; Brown, J.B.; Reid, G.J.; Harris, S. How to obtain excellent response rates when surveying physicians. Fam. Pract. 2009, 26, 65–68. [Google Scholar] [CrossRef] [PubMed]
- Magill, N.; Knight, R.; McCrone, P.; Ismail, K.; Landau, S. A scoping review of the problems and solutions associated with contamination in trials of complex interventions in mental health. BMC Med. Res. Methodol. 2019, 19, 1–13. [Google Scholar] [CrossRef]
- Michie, S.; Johnston, M.; Abraham, C.; Lawton, R.; Parker, D.; Walker, A. Making psychological theory useful for implementing evidence based practice: A consensus approach. Qual. Saf. Health Care 2005, 14, 26–33. [Google Scholar] [CrossRef] [Green Version]
- Cane, J.; O’Connor, D.; Michie, S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement. Sci. 2012, 7, 37. [Google Scholar] [CrossRef] [Green Version]
- Michie, S.; Van Stralen, M.M.; West, R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement. Sci. 2011, 6, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bareham, J. ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects. 2020. Available online: https://www.rxfiles.ca/RxFiles/uploads/documents/Psyc-anticholinergic-Ref%20List%20SPDP-complete.pdf (accessed on 30 April 2021).
- Canada CoFPo. RxFiles. Can. Fam. Physician 2007, 53, 495. [Google Scholar]
- Vaona, A.; Banzi, R.; Kwag, K.H.; Rigon, G.; Cereda, D.; Pecoraro, V.; Tramacere, I.; Moja, L. E-learning for health professionals. Cochrane Database Syst. Rev. 2018, 1, Cd011736. [Google Scholar] [CrossRef] [PubMed]
- IBM Corp. IBM SPSS Statistics for Windows V, 27.0; IBM Corp: Armonk, NY, USA, 2020. [Google Scholar]
- Case, S.M.; Swanson, D.B. Constructing Written Test Questions for the Basic and Clinical Sciences; National Board of Medical Examiners: Philadelphia, PA, USA, 1998. [Google Scholar]
- Zamanzadeh, V.; Ghahramanian, A.; Rassouli, M.; Abbaszadeh, A.; Alavi-Majd, H.; Nikanfar, A.-R. Design and implementation content validity study: Development of an instrument for measuring patient-centered communication. J. Caring Sci. 2015, 4, 165–178. [Google Scholar] [CrossRef]
- Rodrigues, I.B.; Adachi, J.D.; Beattie, K.A.; MacDermid, J.C. Development and validation of a new tool to measure the facilitators, barriers and preferences to exercise in people with osteoporosis. BMC Musculoskelet. Disord. 2017, 18, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Streiner, D.L.; Norman, G.R.; Cairney, J. Health Measurement Scales: A Practical Guide to Their Development and Use; Oxford University Press: Oxford, UK, 2015. [Google Scholar]
- Sinclair, P.M.; Kable, A.; Levett-Jones, T.; Holder, C.; Oldmeadow, C.J. An evaluation of general practice nurses’ knowledge of chronic kidney disease risk factors and screening practices following completion of a case study-based asynchronous e-learning module. Aust. J. Prim. Health 2019, 25, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Van de Steeg, L.; IJkema, R.; Langelaan, M.; Wagner, C. Can an e-learning course improve nursing care for older people at risk of delirium: A stepped wedge cluster randomised trial. BMC Geriatr. 2014, 14, 69. [Google Scholar] [CrossRef] [Green Version]
- Bentley, M.W.; Kerr, R.; Ginger, M.; Karagoz, J. Behavioural change in primary care professionals undertaking online education in dementia care in general practice. Aust. J. Prim. Health 2019, 25, 244–249. [Google Scholar] [CrossRef]
- Kamarudin, G.; Penm, J.; Chaar, B.; Moles, R. Educational interventions to improve prescribing competency: A systematic review. BMJ Open 2013, 3, e003291. [Google Scholar] [CrossRef] [Green Version]
- Lanz, K.; Bishop, D.B. The role of behavioral science theory in development and implementation of public health interventions. Annu. Rev. Public Health 2010, 31, 399–418. [Google Scholar] [CrossRef] [Green Version]
- Stewart, C.; Gallacher, K.; Nakham, A.; Cruickshank, M.; Newlands, R.; Bond, C.; Myint, P.K.; Bhattacharya, D.; Mair, F.S. Barriers and facilitators to reducing anticholinergic burden: A qualitative systematic review. Int. J. Clin. Pharm. 2021, 4, 1451–1460. [Google Scholar] [CrossRef] [PubMed]
- Hussein, R.; Whaley, C.R.; Lin, E.C.; Grindrod, K. Identifying barriers, facilitators and behaviour change techniques to the adoption of the full scope of pharmacy practice among pharmacy professionals: Using the Theoretical Domains Framework. Res. Soc. Adm. Pharm. 2021, 17, 1396–1406. [Google Scholar] [CrossRef]
- Maloney, S.; Haas, R.; Keating, J.L.; Molloy, E.; Jolly, B.; Sims, J.; Morgan, P.; Haines, T. Breakeven, cost benefit, cost effectiveness, and willingness to pay for web-based versus face-to-face education delivery for health professionals. J. Med. Internet Res. 2012, 14, e47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levine, D.A.; Funkhouser, E.M.; Houston, T.K.; Gerald, J.K.; Johnson-Roe, N.; Allison, J.J.; Richman, J.; Kiefe, C.I. Improving Care After Myocardial Infarction Using a 2-Year Internet-Delivered Intervention: The Department of Veterans Affairs Myocardial Infarction–Plus Cluster-Randomized Trial. Arch. Intern. Med. 2011, 171, 1910–1917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pannucci, C.J.; Wilkins, E.G. Identifying and avoiding bias in research. Plast. Reconstr. Surg. 2010, 126, 619. [Google Scholar] [CrossRef] [PubMed]
Demographics | Intervention Group (n = 60) | Control Group (n = 60) |
---|---|---|
Years of pharmacy practice experience | ||
Less than 1 year | 3 (5%) | 6 (10%) |
1–5 years | 14 (23.3%) | 13 (21.6%) |
6–10 years | 9 (15%) | 5 (8.3%) |
11–20 years | 12 (20%) | 15 (25%) |
More than 20 years | 22 (36.6%) | 21(35%) |
Gender | ||
Woman | 44 (73.3%) | 50 (83.3%) |
Man | 13 (21.6%) | 8 (13.3%) |
Prefer not to disclose | 3 (5%) | 2 (3.3%) |
Location of qualifying pharmacy training (e.g., BScPharm, entry level PharmD) | ||
Canada | 45 (75%) | 42 (70%) |
United States | 3 (5%) | 5 (8.3%) |
Outside North America | 12 (20%) | 13 (21.6%) |
Highest level of education | ||
Bachelor | 38 (63.3%) | 38 (63.3%) |
Entry-level PharmD | 10 (16.6%) | 11 (18.3%) |
Masters | 4 (6.6%) | 5 (8.3%) |
Postgraduate PharmD | 6 (10%) | 3 (5%) |
PhD | 1 (1.6%) | 1 (1.6%) |
Other | 1 (1.6%) | 2 (3.3%) |
Primary site of practice | ||
Community: Independent pharmacy | 20 (33.3%) | 22 (36.6%) |
Community: chain or franchise | 22 (36.6%) | 21 (35%) |
Hospital in-patient | 9 (15%) | 8 (13.3%) |
Primary care clinic | 4 (6.6%) | 3 (5%) |
Other | 5 (8.3%) | 6 (10%) |
Training courses related to anticholinergic toxicity in the past 12 months | ||
Yes | 0 | 1 (2.0%) |
No | 60 (100%) | 58 (96.6%) |
Maybe | 0 | 1 (1.6%) |
Pre-Test Score Out of 29 (Mean ± Standard Deviation) | p Value a | ||
---|---|---|---|
Intervention group (n = 60) | Control group (n = 60) | 0.987 | |
19.35 ± 3.56 | 19.22 ± 3.45 | ||
Post-test score out of 29 (mean ± SD) | |||
Intervention group (n = 50) | Control group (n = 51) | ||
22.42 ± 3.812 | 23.29 ± 3.087 | 0.208 | |
p value b | <0.001 | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hussein, R.; He, Z.; Bareham, J.; Patel, T.; Killeen, R.; Grindrod, K. Evaluating the Effectiveness of the Computer-Based Education Platform, Pharmacy5in5, on Pharmacists’ Knowledge of Anticholinergic Toxicity Using a Randomized Controlled Trial. Pharmacy 2022, 10, 8. https://doi.org/10.3390/pharmacy10010008
Hussein R, He Z, Bareham J, Patel T, Killeen R, Grindrod K. Evaluating the Effectiveness of the Computer-Based Education Platform, Pharmacy5in5, on Pharmacists’ Knowledge of Anticholinergic Toxicity Using a Randomized Controlled Trial. Pharmacy. 2022; 10(1):8. https://doi.org/10.3390/pharmacy10010008
Chicago/Turabian StyleHussein, Rand, Zhoushanyue He, Julia Bareham, Tejal Patel, Rosemary Killeen, and Kelly Grindrod. 2022. "Evaluating the Effectiveness of the Computer-Based Education Platform, Pharmacy5in5, on Pharmacists’ Knowledge of Anticholinergic Toxicity Using a Randomized Controlled Trial" Pharmacy 10, no. 1: 8. https://doi.org/10.3390/pharmacy10010008
APA StyleHussein, R., He, Z., Bareham, J., Patel, T., Killeen, R., & Grindrod, K. (2022). Evaluating the Effectiveness of the Computer-Based Education Platform, Pharmacy5in5, on Pharmacists’ Knowledge of Anticholinergic Toxicity Using a Randomized Controlled Trial. Pharmacy, 10(1), 8. https://doi.org/10.3390/pharmacy10010008